此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

在晚期转移性cast割前列腺癌(MCRPC)中对帕斯里塔米与安慰剂的研究 (KLK2-comPAS)

2026年11月2日 更新者:Janssen Research & Development, LLC

帕斯里塔米(JNJ-78278343)的3期随机,双盲,安慰剂对照研究,一种T细胞重定向剂,靶向人类Kallikrein 2, +最佳支持性护理与最佳支持护理的转移性castratiation castration-Cattration-Cantastatic-Cantastatic-Cantastation-Castration-Castration-Castration-Cantastati

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 with JNJ-87189401+BSC as compared to placebo with BSC in participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of cancer that has spread beyond the prostate gland and is no longer responding to hormone therapies).

研究概览

研究类型

介入性

注册 (估计的)

1203

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Beijing、中国、100034
        • 招聘中
        • Peking University First Hospital
      • Changchun、中国、130021
        • 招聘中
        • The First Bethune Hospital of Jilin University
      • Chengdu、中国、610041
        • 招聘中
        • West China Hospital of Sichuan University
      • Chengdu、中国、500643
        • 招聘中
        • The Third People's Hospital of Chengdu
      • Chongqing、中国、400030
        • 招聘中
        • Chongqing University Cancer Hospital
      • Guangzhou、中国、510060
        • 招聘中
        • Sun Yat Sen University Cancer Center
      • Nanjing、中国、210008
        • 招聘中
        • Nanjing Drum Tower Hospital
      • Nanning、中国、530021
        • 招聘中
        • The First Affiliated Hospital of Guangxi Medical University
      • Nantong、中国、226300
        • 招聘中
        • Nantong Tumor Hospital
      • Ningbo、中国、315010
        • 招聘中
        • The First Affiliated Hospital of Ningbo University
      • Shanghai、中国、200032
        • 招聘中
        • Fudan University Shanghai Cancer Center
      • Tianjin、中国、300211
        • 招聘中
        • The Second Hospital Of Tianjin Medical University
      • Wenzhou、中国、325000
        • 招聘中
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan、中国、430071
        • 招聘中
        • Zhongnan Hospital Wu Han University
      • Xi'an、中国、710061
        • 招聘中
        • The First Affiliated Hospital of Xian Jiaotong University
    • Alberta
      • Calgary、Alberta、加拿大、T2N 5G2
        • 招聘中
        • Arthur J E Child Comprehensive Cancer Centre
    • British Columbia
      • Vancouver、British Columbia、加拿大、V5Z 4E6
        • 招聘中
        • BC Cancer Vancouver
    • Ontario
      • Oshawa、Ontario、加拿大、L1G2B9
        • 招聘中
        • Lakeridge Health
      • Toronto、Ontario、加拿大、M4N 3M5
        • 招聘中
        • Sunnybrook Health Sciences Center
      • Toronto、Ontario、加拿大、M5G 2C1
        • 招聘中
        • Princess Margaret Hospital
    • Quebec
      • Québec、Quebec、加拿大、G1J 1Z4
        • 招聘中
        • CHU de Quebec Universite Laval
      • Kaohsiung City、台湾、833
        • 招聘中
        • Chang Gung Memorial Hospital
      • Taichung、台湾、40705
        • 招聘中
        • Taichung Veterans General Hospital
      • Taichung、台湾、435
        • 招聘中
        • Tungs' Taichung MetroHarbor Hospital
      • Taipei、台湾、100
        • 招聘中
        • National Taiwan University Hospital
      • Taipei、台湾、112
        • 招聘中
        • Taipei Veterans General Hospital
      • Taoyuan、台湾、333
        • 招聘中
        • Linkou Chang Gung Memorial Hospital
      • Florianópolis、巴西、88020 210
        • 招聘中
        • Grupo ELORA Centro de Pesquisa e Ensino em Saude de Santa Catarina
      • Joinville、巴西、89201 260
        • 招聘中
        • Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia
      • Natal、巴西、59062 000
        • 招聘中
        • Liga Norte Riograndense Contra O Cancer
      • Porto Alegre、巴西、90035-001
        • 招聘中
        • Hospital Moinhos de Vento
      • São Paulo、巴西、01509 900
        • 招聘中
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • Braunschweig、德国、38126 DE
        • 招聘中
        • Staedtisches Klinikum Braunschweig
      • Duisburg、德国、47169
        • 招聘中
        • Urologicum Duisburg
      • Düsseldorf、德国、40225
        • 招聘中
        • Universitaetsklinikum Duesseldorf
      • Essen、德国、45147
        • 招聘中
        • Universitaetsklinikum Essen
      • Frankfurt am Main、德国、60488
        • 招聘中
        • Krankenhaus NorthWest
      • Hamburg、德国、20246
        • 招聘中
        • Martini-Klinik am UKE GmbH
      • Heidelberg、德国、69120
        • 招聘中
        • Universitaetsklinikum Heidelberg Nationales Centrum fuer Tumorerkrankungen
      • München、德国、81675
        • 招聘中
        • Klinikum rechts der Isar der TU Muenchen
      • Münster、德国、48149
        • 招聘中
        • Universitaetsklinikum Muenster
      • Nuremberg、德国、90419
        • 招聘中
        • Klinikum Nuernberg Nord
      • Nürtingen、德国、72622
        • 招聘中
        • Studienpraxis Urologie Nurtingen
      • Foggia、意大利、71122
        • 招聘中
        • Ospedali Riuniti Foggia
      • Milan、意大利、20133
        • 招聘中
        • Fondazione IRCCS Istituto Nazionale dei Tumori
      • Naples、意大利、80131
        • 招聘中
        • Azienda Ospedaliera Universitaria Federico II
      • Padova、意大利、35128
        • 招聘中
        • IOV IRCCS Padova
      • Palermo、意大利、90127
        • 招聘中
        • Azienda Di Rilievo Nazionale E Di Alta Specializzazione
      • Roma、意大利、00168
        • 招聘中
        • Fondazione Policlinico Universitario A Gemelli IRCCS
      • Rozzano、意大利、20089
        • 招聘中
        • Istituto Clinico Humanitas
      • Torino、意大利、10126
        • 招聘中
        • A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette
      • Bunkyō City、日本、113 8519
        • 招聘中
        • Institute of Science Tokyo Hospital
      • Fukuoka、日本、812 8582
        • 招聘中
        • Kyushu University Hospital
      • Gifu、日本、501-1194
        • 招聘中
        • Gifu University Hospital
      • Hidaka、日本、350 1298
        • 招聘中
        • Saitama Medical University International Medical Center
      • Kanazawa、日本、920 8641
        • 招聘中
        • Kanazawa University Hospital
      • Kashiwa、日本、277 8577
        • 招聘中
        • National Cancer Center Hospital East
      • Kobe、日本、650 0017
        • 招聘中
        • Kobe University Hospital
      • Matsuyama、日本、791-0280
        • 招聘中
        • National Hospital Organization Shikoku Cancer Center
      • Meguro Ku、日本、152 8902
        • 招聘中
        • National Hospital Organization Tokyo Medical Center
      • Sakura、日本、285-8741
        • 招聘中
        • Toho University Sakura Medical Center
      • Sapporo、日本、060 8648
        • 招聘中
        • Hokkaido University Hospital
      • Yokohama、日本、232 0024
        • 招聘中
        • Yokohama City University Medical Center
      • Yokohama、日本、236 0004
        • 招聘中
        • Yokohama City University Hospital
      • Yokosuka、日本、238 8558
        • 招聘中
        • Yokosuka Kyosai Hospital
      • Bruges、比利时、8000
        • 招聘中
        • AZ Sint-Jan
      • Brussels、比利时、1200
        • 招聘中
        • Cliniques Universitaires Saint Luc
      • Ghent、比利时、9000
        • 招聘中
        • Ghent University Hospital
      • Ghent、比利时、9000
        • 招聘中
        • AZ Maria Middelares
      • Kortrijk、比利时、8500
        • 招聘中
        • Az Groeninge
      • La Louvière、比利时、7100
        • 招聘中
        • Chu Helora Hospital La Louviere Site Jolimont
      • Liège、比利时、4000
        • 招聘中
        • CHC MontLegia
      • Ottignies、比利时、1340
        • 招聘中
        • Clinique Saint Pierre
      • Wilrijk、比利时、2610
        • 招聘中
        • ZAS Augustinus
      • Bordeaux、法国、33000
        • 招聘中
        • Institut Bergonie
      • Brest、法国、29200
        • 招聘中
        • CHRU Brest - Hopital Morvan
      • Dijon、法国、21000
        • 招聘中
        • Centre Georges Francois Leclerc
      • Lille、法国、59000
        • 招聘中
        • Centre Oscar Lambret
      • Lyon、法国、69008
        • 招聘中
        • Centre Leon Berard
      • Paris、法国、75014
        • 招聘中
        • Hopital Saint Joseph
      • Pierre-Bénite、法国、69495
        • 招聘中
        • CHU Lyon Sud
      • Saint-Herblain、法国、44805
        • 招聘中
        • I.C.O. Rene Gauducheau
      • Strasbourg、法国、672098
        • 招聘中
        • Hopitaux universitaires de Strasbourg
      • Vandœuvre-lès-Nancy、法国、54519
        • 招聘中
        • Institut de Cancerologie de Lorraine
      • Villejuif、法国、94800
        • 招聘中
        • Gustave Roussy
      • Bialystok、波兰、15 276
        • 招聘中
        • Uniwersytecki Szpital Kliniczny w Bialymstoku
      • Bydgoszcz、波兰、85 048
        • 招聘中
        • IN VIVO Sp. z o.o
      • Koszalin、波兰、75-581
        • 招聘中
        • Szpital Wojewodzki im Mikolaja Kopernika w Koszalinie
      • Warsaw、波兰、02 781
        • 招聘中
        • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
      • Warsaw、波兰、04 073
        • 招聘中
        • Szpital Grochowski Im Dr Med Rafala Masztaka Sp Z O O
      • Rio Piedras、波多黎各、00935
        • 招聘中
        • Pan American Center for Oncology Trials LLC
      • San Juan、波多黎各、00917
        • 招聘中
        • Puerto Rico Medical Research Center
      • Heidelberg、澳大利亚、3084
        • 招聘中
        • Warringal Private Hospital
      • Kurralta Park、澳大利亚、5037
        • 招聘中
        • ICON Cancer Care
      • Melbourne、澳大利亚、3000
        • 招聘中
        • Peter MacCallum Cancer Centre
      • Murdoch、澳大利亚、6150
        • 招聘中
        • Fiona Stanley Hospital
      • Woolloongabba、澳大利亚、4102
        • 招聘中
        • Princess Alexandra Hospital
    • California
      • La Jolla、California、美国、92093
        • 招聘中
        • University of California at San Diego
      • Los Angeles、California、美国、90048
        • 招聘中
        • Cedars Sinai Medical Center
      • Los Angeles、California、美国、90095
        • 招聘中
        • Ronald Reagan UCLA Medical Center
      • San Francisco、California、美国、94121
        • 招聘中
        • San Francisco VA Medical Center
    • Colorado
      • Aurora、Colorado、美国、80045
        • 招聘中
        • University of Colorado Cancer Center
      • Aurora、Colorado、美国、80012
        • 招聘中
        • Rocky Mountain Cancer Centers
      • Lakewood、Colorado、美国、80228
        • 招聘中
        • Colorado Clinical Research
    • Connecticut
      • Hartford、Connecticut、美国、06102
        • 招聘中
        • Hartford Hospital
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20016
        • 招聘中
        • Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital
    • Florida
      • Bay Pines、Florida、美国、33744
        • 招聘中
        • Bay Pines VA Healthcare System
      • Fort Myers、Florida、美国、33901
        • 招聘中
        • Florida Cancer Specialists & Research Institute
      • Tampa、Florida、美国、33612
        • 招聘中
        • Moffitt Cancer Center
    • Iowa
      • Iowa City、Iowa、美国、52242
        • 招聘中
        • University of Iowa Hospital and Clinics
      • Waukee、Iowa、美国、50263
        • 招聘中
        • Mission Cancer Blood
    • Louisiana
      • Metairie、Louisiana、美国、70006
        • 招聘中
        • East Jefferson General Hospital
    • Maryland
      • Baltimore、Maryland、美国、21287
        • 招聘中
        • Johns Hopkins University
    • Massachusetts
      • Boston、Massachusetts、美国、02115
        • 招聘中
        • Dana Farber Cancer Institute
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • 招聘中
        • University of Michigan Health System
      • Detroit、Michigan、美国、48202
        • 招聘中
        • Henry Ford Cancer Detroit
    • Minnesota
      • Minneapolis、Minnesota、美国、55455
        • 招聘中
        • University Of Minnesota Medical Center
    • Nebraska
      • Omaha、Nebraska、美国、68130
        • 完全的
        • XCancer Omaha / Urology Cancer Center
    • New York
      • Brooklyn、New York、美国、11220
        • 招聘中
        • NYU Langone Hospitals
      • Mineola、New York、美国、11501
        • 招聘中
        • NYU Langone Hospital Long Island
      • New York、New York、美国、10032
        • 招聘中
        • Columbia University Medical Center
      • New York、New York、美国、10016
        • 招聘中
        • NYU Langone Health Laura and Isaac Perlmutter Cancer Center
    • North Carolina
      • Charlotte、North Carolina、美国、28204
        • 招聘中
        • Levine Cancer Institute
      • Winston-Salem、North Carolina、美国、27157
        • 招聘中
        • Atrium Health Wake Forest Baptist Comprehensive Cancer Center
    • Ohio
      • Cincinnati、Ohio、美国、45219
        • 招聘中
        • University of Cincinnati
      • Cleveland、Ohio、美国、44106
        • 招聘中
        • University Hospital of Cleveland
    • Oregon
      • Portland、Oregon、美国、97239
        • 招聘中
        • VA Portland Health Care System
      • Portland、Oregon、美国、97227
        • 完全的
        • Compass Oncology
      • Portland、Oregon、美国、97239
        • 招聘中
        • Oregon Health And Science University
      • Springfield、Oregon、美国、97477
        • 招聘中
        • Oregon Urology Institute
    • Pennsylvania
      • Bala-Cynwyd、Pennsylvania、美国、19004
        • 招聘中
        • MidLantic Urology
      • Lancaster、Pennsylvania、美国、17601
        • 招聘中
        • Keystone Urology Specialists
      • Philadelphia、Pennsylvania、美国、19104
        • 招聘中
        • Penn Medicine Abramson Cancer Center
      • Pittsburgh、Pennsylvania、美国、15232
        • 招聘中
        • UPMC Cancer Centers
    • South Carolina
      • Charleston、South Carolina、美国、29401
        • 招聘中
        • Ralph H Johnson Veterans Hospital
      • Greer、South Carolina、美国、29650
        • 招聘中
        • Gibbs Cancer Center and Research Institute Pelham
      • Myrtle Beach、South Carolina、美国、29572
        • 招聘中
        • Carolina Urologic Research Center
      • Spartanburg、South Carolina、美国、29303
        • 招聘中
        • Gibbs Cancer Center
    • Tennessee
      • Chattanooga、Tennessee、美国、37404
        • 招聘中
        • Tennessee Oncology - Chattanooga
      • Nashville、Tennessee、美国、37203
        • 招聘中
        • Tennessee Oncology Nashville
    • Texas
      • Dallas、Texas、美国、75390
        • 招聘中
        • UT Southwestern Medical Center
      • Dallas、Texas、美国、75231
        • 完全的
        • Urology Clinics of North Texas
      • Houston、Texas、美国、77030
        • 招聘中
        • MD Anderson Cancer Center
      • Houston、Texas、美国、77030
        • 招聘中
        • Michael E DeBakey VA Medical Center
      • Wichita Falls、Texas、美国、76310
        • 招聘中
        • Texas Oncology West Texas
    • Utah
      • Salt Lake City、Utah、美国、84106
        • 招聘中
        • Utah Cancer Specialists
    • Virginia
      • Fairfax、Virginia、美国、22031
        • 招聘中
        • Virginia Cancer Specialists
      • Norfolk、Virginia、美国、23502
        • 招聘中
        • Virginia Oncology Associates
      • Roanoke、Virginia、美国、24014
        • 招聘中
        • Blue Ridge Cancer Care
    • Washington
      • Seattle、Washington、美国、98195
        • 招聘中
        • University of Washington
      • Seattle、Washington、美国、98109
        • 招聘中
        • Fred Hutchinson Cancer Research Center
      • Seattle、Washington、美国、98108
        • 招聘中
        • VA Puget Sound Healthcare System
      • Birmingham、英国、B15 2TH
        • 招聘中
        • University Hospitals Birmingham NHS Foundation Trust
      • London、英国、WC1E 6BT
        • 招聘中
        • University College London Hospitals
      • Manchester、英国、M20 4BX
        • 招聘中
        • The Christie NHS Foundation Trust Christie Hospital
      • Sutton、英国、SM2 5PT
        • 招聘中
        • Royal Marsden Hospital (Sutton)
      • Delft、荷兰、2625 AD
        • 招聘中
        • Reinier de Graaf Gasthuis
      • Groningen、荷兰、9728NT
        • 完全的
        • Martini Ziekenhuis
      • Hilversum、荷兰、1212 VG
        • 招聘中
        • Tergooi
      • Hoofddorp、荷兰、2134 TM
        • 招聘中
        • Spaarne Gasthuis
      • Maastricht、荷兰、6229 HX
        • 招聘中
        • Maastricht UMC
      • Nijmegen、荷兰、6532 SZ
        • 招聘中
        • Canisius-Wilhelmina ZH
      • Rotterdam、荷兰、3015 GD
        • 招聘中
        • Erasmus MC
      • Zwolle、荷兰、8025 AB
        • 招聘中
        • Isala Kliniek
      • Barcelona、西班牙、08035
        • 招聘中
        • Hosp Univ Vall D Hebron
      • Jerez de la Frontera、西班牙、11407
        • 完全的
        • Hosp. de Jerez de La Frontera
      • Madrid、西班牙、28034
        • 招聘中
        • Hosp. Univ. Ramon Y Cajal
      • Madrid、西班牙、28041
        • 招聘中
        • Hosp. Univ. 12 de Octubre
      • Málaga、西班牙、29010
        • 招聘中
        • Hosp Virgen de La Victoria
      • Daejeon、韩国、35015
        • 招聘中
        • Chungnam National University Hospital
      • Goyang-si、韩国、10408
        • 招聘中
        • National Cancer Center
      • Hwasungun、韩国、58128
        • 招聘中
        • Chonnam National University Hwasun Hospital
      • Seoul、韩国、05505
        • 招聘中
        • Asan Medical Center
      • Seoul、韩国、06351
        • 招聘中
        • Samsung Medical Center
      • Seoul、韩国、03722
        • 招聘中
        • Severance Hospital Yonsei University Health System
      • Seoul、韩国、06591
        • 招聘中
        • The Catholic University of Korea Seoul St Marys Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

男性

描述

Inclusion Criteria

  • Histologically confirmed adenocarcinoma of the prostate
  • Metastatic castration-resistant prostate cancer (mCRPC): Disease that is metastatic either to bone, any lymph node, or both without clear evidence of other metastatic sites at the time of screening by conventional imaging with computed tomography (CT) or magnetic resonance imaging (MRI) (chest, abdomen, and pelvis) and 99m^Tc bone scan. Visceral disease is not allowed
  • PSA greater than or equal to (≥) 2 nanogram per milliliter (ng/mL) at screening
  • In the opinion of the investigator, the next best treatment option is a clinical trial
  • Participants are required to have had all life-prolonging therapies for which they are clinically eligible in the opinion of the investigator and to which they have access. Prior therapies could have been given in any disease setting (not limited to mCRPC). In particular, prior treatment specifications include receipt of the following:

Androgen-receptor pathway inhibitor (ARPI): Must have progressed on at least 1 ARPI and unlikely to benefit from retreatment with another ARPI

Taxanes: Required to have received at least 2 previous taxane-based regimens. If a participant has received only 1 taxane regimen, the participant is eligible if:

  1. Cabazitaxel is not available
  2. The participant's physician deems the participant unsuitable to receive a second taxane regimen due to toxicity risk or prior intolerance Note: a taxane-based regimen consists of at least 2 cycles of a taxane (either as a single agent or in combination with other therapies) administered within the same 2-month period

Radioligand therapy: Required to have been previously treated with at least 1 dose of Prostate-specific membrane antigen (PSMA)-targeted lutetium radioligand therapy (eg, lutetium Lu-177 vipivotide tetraxetan), unless one of the following applies:

  1. PSMA-targeted lutetium radioligand therapy is unavailable, not accessible, or not clinically indicated.
  2. The participant's physician deems the participant unsuitable to receive PSMA-targeted lutetium radioligand therapy.

Polyadenosine diphosphate-ribose polymerase inhibitors (PARPi): Required to have been previously treated with PARPi, if the participant has a known germline or somatic BRCA mutation and treatment is available

  • Prior orchiectomy or medical castration (receiving ongoing ADT with a GnRH analog [agonist or antagonist]) prior to the first dose of study treatment and must continue this therapy throughout the treatment phase
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Participants are eligible if they have the following values:

A) eGFR ≥ 40 milliliters per minute (mL/min) B) Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) less than or equal to (≤) 3 times the Upper Limit of Normal (ULN) C) Total bilirubin <1.5 times ULN D) Absolute neutrophil count (ANC) ≥ 1.0x10^9/per liter (L) E) Hemoglobin ≥ 8.0 grams per deciliter (g/dL) F) Platelet count ≥ 75x10^9/L

Exclusion Criteria

  • Venous thromboembolic events within 1 month prior to the first dose of study treatment; uncomplicated (Grade ≤ 2) deep vein thrombosis is not exclusionary
  • Active autoimmune disease within the past 12 months that requires systemic immunosuppressive medications (eg, chronic corticosteroid, methotrexate, or tacrolimus)
  • Participants with Grade 1 or higher fever (≥38ºC) or active infection requiring systemic treatment within 7 days prior to randomization are ineligible. Participants must be afebrile (<38ºC) at the time of study treatment dosing unless approved by medical monitor
  • Clinically significant pulmonary compromise, particularly a requirement for supplemental oxygen use (>2 liters per minute (L/min) by nasal cannula) to maintain adequate oxygenation
  • Prior or concurrent second malignancy (other than the disease under study) for which natural history or treatment could likely interfere with any study endpoints of safety or the efficacy of the study treatment(s)
  • Any of the following within 6 months prior to first dose of study treatment:

A) Myocardial infarction B) Severe or unstable angina C) Clinically significant ventricular arrhythmias D) Congestive heart failure (New York Heart Association class II to IV) E) Transient ischemic attack F) Cerebrovascular accident

- Prior treatment with any CD3-directed therapy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Part 1: Pasritamig+Best Supportive Care (BSC)

Participants in Part 1 will receive 2 step-up doses of pasritamig intravenously (IV) followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician.

Pasritamig will be administrated through IV infusion.

其他名称:
  • JNJ-78278343

BSC will be administered at the discretion of the treating physician.

安慰剂比较:Part 1: Placebo+BSC

Participants in Part 1 will receive 2 step-up doses of placebo IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician.

BSC will be administered at the discretion of the treating physician.

Placebo will be administrated through IV infusion.

实验性的:Part 2: Pasritamig+BSC

Participants in Part 2 will receive 2 step-up doses of pasritamig IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician.

Pasritamig will be administrated through IV infusion.

其他名称:
  • JNJ-78278343

BSC will be administered at the discretion of the treating physician.

实验性的:Part 2: Pasritamig+JNJ-87189401+BSC

Participants in Part 2 will receive 2 step-up doses of pasritamig IV followed by the target dose. JNJ-87189401 will be administered with the first target dose of pasritamig. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician.

Pasritamig will be administrated through IV infusion.

其他名称:
  • JNJ-78278343

BSC will be administered at the discretion of the treating physician.

JNJ-87189401 will be administered.

安慰剂比较:Part 2: Placebo +BSC

Participants in Part 2 will receive 2 step-up doses of placebo IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician.

BSC will be administered at the discretion of the treating physician.

Placebo will be administrated through IV infusion.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Overall Survival (OS)
大体时间:Up to 2 years and 8 months

OS is defined as the time from randomization to date of death due to any cause.

Up to 2 years and 8 months

次要结果测量

结果测量
措施说明
大体时间
Radiographic Progression-free Survival (rPFS)
大体时间:Up to 2 years and 8 months

rPFS assessed by investigator defined as the time from the date of randomization until the date of radiographic disease progression (based on response evaluation criteria in solid tumors [RECIST] version (v) 1.1 and prostate cancer working group 3 [PCWG3] criteria) or death, whichever comes first.

Up to 2 years and 8 months
Time to Symptomatic Progression
大体时间:Up to 2 years and 8 months

Time to symptomatic progression is defined as time from the date of randomization to the date of any of the following (whichever occurs first): (a) the use of external beam radiation therapy to relieve cancer-related symptoms; (b) the need for tumor-related orthopedic surgical intervention; (c) other cancer-related procedures; (d) cancer-related morbid events; (e) initiation of a new systemic anti-cancer therapy because of cancer symptoms.

Up to 2 years and 8 months
Time to Skeletal-Related Event
大体时间:Up to 2 years and 8 months

Time to skeletal-related event is defined as the time from the date of randomization to the date of first occurrence of any of the following (whichever occurs first): (a) the use of external beam radiation for skeletal or pelvic symptoms; b) the need for tumor-related orthopedic surgical intervention; (c) the occurrence of new bone fractures (cancer-related); (d) the occurrence of tumor-related spinal cord compression.

Up to 2 years and 8 months
Progression-Free Survival (PFS)
大体时间:Up to 2 years and 8 months

PFS is defined as the date of randomization to the date of first evidence of radiographic progression, clinical progression, or death from any cause, whichever occurs first.

Up to 2 years and 8 months
Time to Prostate Specific Antigen (PSA) Progression
大体时间:Up to 2 years and 8 months

Time to PSA progression, defined as the time from randomization to the first date of documented PSA progression per PCWG3 criteria. PSA progression is defined as: after a decline from baseline, PSA increases >= 25 percentage (%) and >= 2 nanograms per milliliter (ng/mL) above the nadir, confirmed by a second value >= 3 weeks later (that is, a confirmed rising trend), or If there is no decline from baseline, PSA increases >= 25 % and >= 2 ng/mL from baseline after 12 weeks.

Up to 2 years and 8 months
Time to Pain Progression (TTPP) as Assessed by the Brief Pain Inventory-Short Form (BPI-SF) Item 3 Worst Pain in 24 Hours
大体时间:Up to 2 years and 8 months

TTPP is defined as the time from the date of randomization to the date of the first observation of pain progression. Pain progression is defined as an increase of at least 2 points from baseline in the BPI-SF worst pain intensity (item 3) observed at 2 consecutive evaluations >= 3 weeks apart. BPI-SF is an 11-item questionnaire, designed to assess severity and impact of pain on daily functions. Total score range from 0 to 10 with 0 representing "no pain" and 10 representing" pain as bad as you can imagine".

Up to 2 years and 8 months
Time to Deterioration in Fatigue as Assessed by the European Organisation For Research And Treatment of Cancer Quality of Life Questionnaire-Core-30 (EORTC QLQ-C30) Fatigue Scale Score
大体时间:Up to 2 years and 8 months

Time to deterioration is defined as the time from randomization to the date of the first observation of deterioration in Fatigue. Deterioration in Fatigue is defined as an increase of 10 points on the EORTC QLQ-C30 FA scale observed at 2 consecutive evaluations >= 3 weeks apart. The EORTC QLQ-C30 is a widely used tool for assessing the quality of life of cancer patients in clinical trials. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent". Each subscale of the EORTC QLQ-C30 is scored on a range from 0 to 100. Higher scores indicate worse symptoms or problems.

Up to 2 years and 8 months
Number of Participants with Adverse Events (AEs)
大体时间:Up to 2 years and 8 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Up to 2 years and 8 months
Number of Participants with Abnormalities in Clinical Laboratory Assessments
大体时间:Up to 2 years and 8 months

Participants with abnormalities in clinical laboratory parameters (hematology, clinical chemistry etc.) will be assessed.

Up to 2 years and 8 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年9月2日

初级完成 (估计的)

2028年8月18日

研究完成 (估计的)

2028年8月18日

研究注册日期

首次提交

2025年9月4日

首先提交符合 QC 标准的

2025年9月4日

首次发布 (实际的)

2025年9月10日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 78278343PCR3001
  • 2025-520927-26-00 (注册表标识符:EUCT number)
  • 2025 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅